Researchers have achieved a major breakthrough in liver cancer treatment by combining traditional radiation therapy with microbubble ultrasound contrast agents. The studies found patients with aggressive intrahepatic cholangiocarcinoma (ICC) and liver metastasis showed a greater than 50% improvement in tumor response rates, while patients with hepatocellular carcinoma (HCC) experienced significant improvements in both tumor response and survival.
The treatment works by enhancing standard radioembolization therapy, which uses radioactive yttrium-90 filled glass beads delivered to tumors through a catheter. The addition of microbubble contrast agents and ultrasound appears to boost the effectiveness of this radiation treatment.
This approach is particularly promising because the microbubble agents don’t contain iodine or gadolinium and aren’t toxic to the kidneys, making them safer than many contrast agents. While previous studies showed success with this enhanced radiotherapy approach for breast and head/neck cancers, these are the first trials demonstrating its safety and effectiveness specifically for liver cancer.